ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) Russian patent published in 2017 - IPC C07K16/22 A61P35/00 A61K39/395 C07K16/32 

FIELD: biotechnology.

SUBSTANCE: method is described for blocking or reducing recurrent tumour growth or recurrent growth of cancer cells, comprising administering an effective amount of an anti-VEGF antibody to a subject in need of such treatment, wherein the anti-VEGF antibody comprises: HVR-H1 comprising the amino-acid sequence of SEQ ID NO: 1; HVR-H2 comprising the amino-acid sequence of SEQ ID NO: 2; HVR-H3 comprising the amino-acid sequence of SEQ ID NO: 3; HVR-L1 comprising the amino-acid sequence of SEQ ID NO: 4 or 5; HVR-L2 comprising the amino-acid sequence of SEQ ID NO: 6; and HVR-L3 comprising the amino-acid sequence of SEQ ID NO: 7, or wherein the anti-VEGF antibody comprises a heavy chain variable domain comprising the amino-acid sequence of SEQ ID NO: 43 and a light chain variable domain comprising an amino-acid sequence of SEQ ID NO: 44 or 45. A method of treating a non-neoplastic condition is also described is, comprising administering an effective amount of an anti-VEGF antibody to a subject in need of such treatment, wherein the anti-VEGF antibody is an antibody according to the above method.

EFFECT: increased efficiency.

19 cl, 16 dwg, 5 ex